Quince Therapeutics Stock Pauses After Volatile Biotech Moves
Quince Therapeutics shares closed Friday at $1.10, up 2.8% for the day but down 4.3% for the week. Nasdaq confirmed Quince regained listing compliance after reporting $15.7 million in stockholders’ equity. The company announced the acquisition of Orphai and a planned $187 million private financing. Markets were closed Monday for Memorial Day; trading resumes Tuesday.